As of 4:02pm ET
| -0.09 / -0.20%|
Sanofi engages in the research, production and distribution of pharmaceutical products. It operates through the following segments: Pharmaceuticals, Human Vaccines, Animal Health, and Others. The Pharmaceuticals segment includes research, development, production and sales activities relating to pharmaceutical products, including prescription, consumer health care, and generic products. This segment also includes equity affiliates and joint ventures with pharmaceutical business activities. The Human Vaccines segment includes research, development, production and marketing of vaccines. The Animal Health segment comprises the research, development, production and marketing activities for Merial, which offers a range of medicines and vaccines for a wide variety of animal species. The Others segment includes all activities that do not qualify as reportable segments under IFRS 8 “Operating Segments”; it also includes the effects of retained commitments in respect of divested businesses. The company was founded in 1994 and is headquartered in Paris, France.
|Olivier Brandicourt||Chief Executive Officer|
|JÃ©rÃ´me Contamine||Chief Financial Officer & EVP-Finance|
|Elias E. Zerhouni||President-Global Research & Development|
|Andrew Purcell||Vice President & Head-US Diabetes Business Unit|
|Rafick G. Henein||VP, Global Brand Leader-Toujeo & Diabetes|